(Updated - September 26, 2017 11:02 AM EDT)

(updated to add analyst comment)Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Axovant Sciences (AXON) PT Lowered to $9 at Evercore ISISeptember 26, 2017 12:07 PM Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains FocusSeptember 26, 2017 11:48 AM Oppenheimer Downgrades Axovant Sciences (AXON) to PerformSeptember 26, 2017 10:48 AM UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital MarketsSeptember 26, 2017 9:49 AM Top five unique options volume: AMAT EFX NKE AXON GESeptember 26, 2017 9:46 AM Baird Downgrades Axovant Sciences (AXON) to Neutral, $6 PTSeptember 26, 2017 9:38 AM Pre-Open Movers 09/26: (IZEA) (ASNA) (GHL) Higher; (AXON) (GNCA) (KDMN) Lower (more...)September 26, 2017 9:30 AM Axovant Sciences (AXON) Sinks 70% as Trading ResumesSeptember 26, 2017 7:32 AM Form 8-K Axovant Sciences Ltd. For: Sep 26September 26, 2017 7:07 AM Axovant Sciences (AXON) to Resume Trading at 7:30 AM ETSeptember 26, 2017 7:05 AM Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy EndpointsSeptember 26, 2017 7:02 AM Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's DiseaseSeptember 26, 2017 7:00 AM